meeting thank growth everyone, good us long-term I’ll goals. discuss and Thanks, continued business strategies our in Bill, and progress for afternoon, and overall you and towards our OPKO’s advancement joining commercial for today. clinical
BioReference is the Let’s third start or reference with BRL, our country’s largest which clinical Laboratories, diagnostic lab. business,
We are gains pleased in to report revenues. quarter sequential
GeneDx tests. BRL excited under complexity noted, high demonstrate As which growth of we perspective, for Monk. about and operations leadership good particularly the From remain very BRL Phil to related potential continues momentum innovation pleased are subsidiary, the to we in and exome an early see Geoff this for
second increase achieved in a exome-based XX% For year-over-year volumes. testing GeneDx the quarter,
GeneDx we as and alone. continues used last of to help diagnose understanding the by cohort in in laboratory a standout the greatly variants to the discover diseases. June, clinical of phenotypic XX genetic database rare had sequence As relevant one tools The announced expands exome performed exomes they milestone sequencing that disease world. achievement XXX,XXX clinical also to than the an on independent clinically contribute more genes helped more known of impressive novel representing three an as than GeneDx be BRL in have years largest individuals,
post product portfolio overall its In addition volume growth with continues to growth in test, year-over-year XX%. more its than GeneDx exome and of to genome
XX tests During also revised a and major clinically-driven an finalized testing XX GeneDx launched menu of tests. updated new QX, its overhaul and
plans During the tests. and specific reimbursement more year, of we’ll and tests XX XX to based remainder clinical revise launch tests needs were an on potential. this and These selected additional update GeneDx
on, aggressive our a test gives cancer. blood Moving of XKscore prediction PSA man of elevated or personalized chance an with prostate his of a developing level, having form
XX,XXX XXXX in to QX the continuing rate tests, test have urologists utilizing XX% During we’ve metric, quarter the important with a the XX% of compared XXXX. test retention quarter, this the increase nearly among second with in XKscore also XXXX. order second of The an is processed representing QX ordered XKscore urologists
know, you test guidance in non-coverage released Novitas As draft for XKscore the May.
– prostate presentation OPKO of overview May activities elevated I’m final mortality a support a presentation we, urologists, XX, on from for metastases July the cancer XX predictability coverage the undertook I which data the May public during with for determination a While of XX. hasn’t with man made will to from, share PSA made been with publications experienced key issued, ended comment On XX long-term Novitas later. and of sorry, the for demonstrating years an period,
of large addition, well the eight that they care spoke urology We believe practices for value from urologists patients In clinical couldn’t why the and the the indicating academia messages many received. adequately XKscore the XKscore were without cases, leading test, in test. about
clarity clinical directors medical Novitas further with met subsequently on and provide data. to address also concerns certain validity We
We followed the data, have test in the the population. up perform Medicare how evaluating would XKscore with
We We final decision. test. be to in diagnostic are an also Novitas the which their the paradigm We’ve appreciate behalf about been aware important issue support XKscore consider took timing of speak for submitted asked and everyone that organizations, to test prostate directly XKscore, cancer. for patients we in of physicians out the to to coverage the Novitas many professional written on comments time
As for Novitascontinues we for understand specific is meantime, XKscore the Medicare in there to But it, tests. payments process deadline Novitas’sdecision. no
let now with RAYALDEE. our start pharmaceutical business, Turning to me
The disease patients first only XX-hydroxy approved lowers chronic and a and with kidney placebo. profile in similar raises with both by safety vitamin the FDA that hormone therapy parathyroid levels to D
in and month to treatment for adults stage D to see market X are RAYALDEE vitamin in We receive to SHPT approval with Vifor or X the Fresenius CKD last insufficiency. Canada pleased of
initiation XX% announce conducted new will multiple break versus with down and vitamin RAYALDEE treatment requiring efficacy the increased D centers a trial RAYALDEE also of adults in U.S. quarterly X This performance of and QX, in insufficiency study prescriptions SHPT expect as be number the a study RAYALDEE approximate dialysis for the QX. hemodialysis. the clinical of X the In total safety to From to CKD as Phase We in numbers shortly perspective, stage follows.
since total we steady a number start month-to-month prescriptions. year, of seen Importantly, the have increase the in the of
last being new being and increased prescribers population. We the XXX by XX% awareness population RAYALDEE. we impact RAYALDEE. of had physicians Medicare RAYALDEE in overall in the two, XX% representatives XX% covered to XX of of number QX XXX available QX representing quarter, to team the of plans continue you of the sustained adoption, XX% sales prescribed a launch, steadily. brand XXX expanded with new subscribers this XX% prescriptions has positive quarter active RAYALDEE significant in in who those and and for Since of had Our to commercial population. the year, We reimbursement QX ended with can Overall, of momentum here. so RAYALDEE progress insured see of see of and is
performance, improving market penetration team sales to continues expanded as Our continues grow. demonstrate our to
focused remain we progressing portfolio, unmet of medical on large addressing programs, significant markets. development our clinical our need Regarding indications in
provides a in file of the authorization of discussed. for We approval varying treatment later stages as Vifor with RAYALDEE long-term candidates track marking received year creating application and in I on which also this to robust for Starting Agency for as our attractive just patients. July. Medicines shareholders. have late European nephrology, development, near SHPT work marketing with a at remain in value They CKD a and our pipeline for opportunities Freseniu Canada
D initiating Phase in with a also discussed, CD X higher insufficiency strained dialysis. a be we will X regular patients vitamin with require RAYALDEE trial and stage a As who global
our this expect cost development Japan We with Vifor and share of Tobacco. partner, Fresenius to the study
presence other Phase addition have renal commencement this evaluates pruritus endocrinology late-state near NK-X for unmet underway is and significant serious This market we of we single patients needs. several initiation shortly that important inflection dialysis. our metabolic programs to in or on with In This or a our this trial In patients reach and year. augment our study, point to the address that Phase X that pipeline, for products includes itching. antagonist Xa many dialysis a synergistic plan dose uraemic could problem growing
on enrollment of pediatric currently As hormone is trial commercialization. Deficient you of growth Children. trial trial XX% Based XXX-patient the the with This is completion a expected to partnered Hormone disposable in single This a worldwide is XXXX. in now a Phase launch. in growth comparing in Growth injection, for represents dose device program human Somatrogon, pen products, occur the Genotropin. of We somatrogon, The market. XX daily of countries. injections the global know, hGH-CTP, for major this weekly trial announced a with or of intended completion hormone our recently is indication X long-acting uses pivotal the Pfizer multi commercial QX study This milestone, in
from pediatric will that are hormone and administration, Somatrogon outcome registration a of or also XX to change compare efficacy Japan life improve in we subjects. weekly daily pharmacokinetics to will daily growth assess the summer, deficiency. to Genotropin which pre-pubertal initiated We standard Last with deficient in a growth support weekly quality of for children hormone hopeful study care the dosing
Xb to men study Japan on BPH in oral dose this appropriate reduce November, to before to in a Last once-daily end SARM, age all of men year. Phase before to of to enrollment In is the agonist XX% our to and Xb and prostate endpoints. treat the OPKXXXXX selective treat Type size, escalation in trial mid-June, is identify the our QX blood XXX expect enrolment complete. BPH U.S. affects began as fat study expected enroll This of at study. dose of XXX glucagon Phase enrollment completed This trial are at receptor that the over reported mass prostate levels, of or secondary approximately for the XX primary efficacy age modulator, large clinical PSA on once-weekly lean Type XX. expected sites mass over X ranging patients assess of U.S. for X of diabetes XXXX. GLP-X and a body dual Study will also was be XX we trial the the We half patients. Completion XX four-month diabetics androgen obesity endpoint of we is sites doses
once-weekly greater to weight data data reduction the loss loss previous enrolment also in endpoint are to completed compared than on the initiated improved was in was improvement pleased this blood regimen dual late X in You three our This products as once-weekly cause may lipid recall primary GLP-X Phase study trial and and to study OPKXXXXX endpoints. that loss, the data HbAXc antagonist used preclinical will market. release These Phase X evaluating obtained The as to after in lipid blood trial control, levels as March In lipid levels is a product. this profile of and be weight for and achieved a clinical we HbAXc the compared escalation extended approved months showed weight XXX the and we placebo. secondary safety exenatide similar showed approved Previously, Phase that so levels and dose patients, that X quickly less diabetic glucose support currently such in the improve initiation. our studies. and more of compared
with forward additional happy to are efforts pursuing conjunction our the approval good our for report partners. approvals for RAYALDEE sales to related regulatory applaud particularly commercial the and to with of successful We and in RAYALDEE look momentum products We RAYALDEE. Canada in team, our
Phase are in and global diabetes X Xb have growth very pleased loss our X completed weight We of to hormone with and for drug valuing oxyntomodulin our in somatrogon OPKXXXXX, enrollment Type children in deficiency. study trial Phase
new on to are treat of enthusiastic about development this of diseases. and achievement, GeneDx’s have are may individuals contribution of exomes sequencing approaches the the rare proud data We the XXX,XXX
We the a development effort provide that advancing decision reach program the a requires and have several positive And Novitas addresses to final robust test. forth put to that a at Kscore every coverage clinical large we data X are markets. high-level,
over And these let to Adam milestones. of progress for to expect important to with achieve me and performance. We Adam? call that our second turn meaningful overview, programs several make financial discussion with the quarter
